Thus, identifying that the PML:RARα fusion protein provided the basis of Mechanism of Action for ATRA in APL was reported six years after the first PoC patient was treated and post-dating the first reports of Mode of Action-informed larger clinical trials by 2-3 years (Fig. 2). The gene discussed is RARA; the disease is acute promyelocytic leukemia.